BIIB BIOGEN INC.
Price Chart
Executive Summary
Wells Fargo initiated a double upgrade from Equal-Weight to Overweight on the stock with a $250 price target, up from $200, citing improved fundamentals and valuation support. The move contrasts with a slightly bearish EPS revision trend, where 30-day estimates show more downgrades than upgrades across all periods. Consensus remains mixed: 40% Buy, 36.7% Hold, 3.3% Sell, with a mean target of $207.69 — Wells Fargo’s $250 PT is 20.4% above the mean. Institutional activity is split: FMR and Norges Bank made large new or expanded positions, while Renaissance and Wells Fargo Asset Management trimmed. Short interest is extremely elevated at 67.2% short ratio. With earnings due in nine days, this contrarian call from a firm with 55% accuracy (3.6% avg return) adds urgency. The rating change is a bullish outlier against a weakening analyst momentum backdrop.
Impact Score
Consensus & Targets
Of 33 analysts, 40% rate Buy (13), 36.7% Hold (11), 3.3% Sell (1), and 0% Strong Sell. Consensus direction is neutral-to-slightly positive, though the high Hold count (22) reflects lingering caution. The upgrade from Wells Fargo moves it into the bullish minority.
The consensus mean price target is $207.69, median $203.50, range $150–$275. At a current price of $177.35, this implies 17.1% upside to the mean. Wells Fargo’s $250 target is 20.4% above the mean and 9.7% below the high target of $275, placing it in the top quartile of bullishness.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-20 | Wells Fargo | upgrade | Overweight | $250.00 |
| 2026-04-14 | Piper Sandler | upgrade | Overweight | $214.00 |
| 2026-04-13 | Citigroup | maintain | Neutral | $190.00 |
| 2026-04-13 | Truist Securities | maintain | Hold | $189.00 |
| 2026-04-10 | Morgan Stanley | maintain | Equal-Weight | $200.00 |
| 2026-04-02 | HC Wainwright & Co. | maintain | Buy | $237.00 |
| 2026-04-01 | Canaccord Genuity | maintain | Buy | $245.00 |
| 2026-04-01 | Oppenheimer | maintain | Outperform | $275.00 |
| 2026-03-17 | HSBC | maintain | Reduce | $150.00 |
| 2026-02-23 | Freedom Broker | maintain | Hold | $185.00 |
Over the past 30 days, there have been 2 upgrades (Wells Fargo, Piper Sandler) and 0 downgrades. EPS revisions are trending down: in the last 30 days, 4 downward revisions vs 0 upward for current year EPS; next year shows 1 up, 1 down. The 7-day revision trend shows minor stabilization with 2 upward revisions in the past week.
Firm Track Record — Wells Fargo
Wells Fargo accuracy: 55% on 6035 calls | avg return: 3.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Jefferies | 100% | 2/2 | 13% | top tier |
| Morgan Stanley | 83% | 5/6 | 5.5% | top tier |
| Piper Sandler | 71% | 5/7 | 1.6% | top tier |
| Wedbush | 67% | 4/6 | 2.1% | top tier |
| JP Morgan | 67% | 2/3 | 2.5% | top tier |
| HC Wainwright & Co. | 57% | 4/7 | 1.4% | above average |
| UBS | 50% | 1/2 | 0.6% | below average |
| Barclays | 50% | 2/4 | -2.8% | below average |
| Canaccord Genuity | 50% | 1/2 | -2.1% | below average |
| Goldman Sachs | 50% | 1/2 | -0.1% | below average |
Wells Fargo has a 55% accuracy rate (3,290 correct out of 6,035 rated calls) and an average return of 3.6% on rated stocks, placing it slightly above average. Among 15 firms covering the stock, it ranks 7th in accuracy — behind top-tier firms like Jefferies (100%), Morgan Stanley (83%), and Piper Sandler (71%), but ahead of UBS (50%) and RBC (47%).
Earnings Estimates
Next earnings: Apr 29, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $3.01 | $1.66 — $4.68 | $2.3B | ↑1 ↓0 |
| +1q | $4.37 | $3.95 — $5.04 | $2.4B | ↑0 ↓0 |
| 0y | $15.62 | $14.02 — $16.33 | $9.4B | ↑2 ↓0 |
| +1y | $15.88 | $14.34 — $17.60 | $9.4B | ↑2 ↓0 |
Cross-Platform Signals
Institutional activity shows divergence: FMR LLC doubled down (+632%), and Norges Bank initiated a $464M position, signaling strong fundamental conviction. However, Renaissance Technologies slashed its stake by 58.6%, and Wells Fargo’s own asset arm trimmed by 32.3%. No insider trades reported. Congressional buys are minimal (1 small buy). Short interest is extreme at 67.2% short ratio, suggesting high bearish positioning ahead of earnings.
Actionable Insight
A double upgrade from a mid-tier accuracy firm nine days before earnings, combined with aggressive institutional divergence and extreme short interest, sets up a high-conviction catalyst trade. Position for a short squeeze if results beat.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 13, 2026
1d ago
|
ANALYST-UPGRADE
| $176.40 awaiting T+1 | awaiting T+1 | — | $200.05 (+13.41%) |
|
Jun 8, 2026
6d ago
|
ANALYST-UPGRADE
| $194.60 awaiting T+1 | awaiting T+1 | — | $200.05 (+2.80%) |
|
Jun 4, 2026
11d ago
|
Press Release
| $195.82 $195.30 | ▼ −0.27% | ▲ +2.33% | $200.05 (+2.16%) |
|
Jun 1, 2026
14d ago
|
Press Release
| $192.22 $188.66 | ▼ −1.85% | ▼ −2.00% | $200.05 (+4.08%) |
|
May 31, 2026
14d ago
|
ANALYST-UPGRADE
| $156.63 $154.99 | ▼ −1.05% | ▼ −1.18% | $200.05 (+27.72%) |
|
May 22, 2026
23d ago
|
ANALYST-UPGRADE
| $190.12 $187.84 | ▼ −1.20% | ▼ −0.81% | $200.05 (+5.22%) |
|
May 21, 2026
24d ago
|
Press Release
| $193.85 $193.07 | ▲ +0.40% | ▲ +0.99% | $200.05 (−3.20%) |
|
May 20, 2026
25d ago
|
ANALYST-UPGRADE
| $183.33 $185.18 | ▲ +1.01% | ▲ +1.66% | $200.05 (+9.12%) |
|
May 14, 2026
4w ago
|
ANALYST-UPGRADE
| $178.76 $180.47 | ▲ +0.96% | ▲ +0.18% | $200.05 (+11.91%) |
|
May 14, 2026
4w ago
|
Press Release
| $191.26 $192.32 | ▲ +0.55% | ▲ +1.78% | $200.05 (+4.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access